Endurance (Cayman) Ltd Svf Sells 127,938 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 127,938 shares of the business’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $6.39, for a total value of $817,523.82. Following the completion of the sale, the insider owned 13,982,271 shares in the company, valued at $89,346,711.69. The trade was a 0.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Friday, November 28th, Endurance (Cayman) Ltd Svf sold 61,493 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.44, for a total transaction of $396,014.92.
• On Tuesday, November 25th, Endurance (Cayman) Ltd Svf sold 235,971 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.38, for a total transaction of $1,505,494.98.
• On Monday, November 24th, Endurance (Cayman) Ltd Svf sold 227,803 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.15, for a total transaction of $1,400,988.45.
• On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.49, for a total transaction of $649.00.
• On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.50, for a total transaction of $158,944.50.
• On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.05, for a total transaction of $401,738.15.
• On Friday, October 24th, Endurance (Cayman) Ltd Svf sold 46,696 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.96, for a total transaction of $278,308.16.
• On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.99, for a total value of $924,754.17.
• On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.15, for a total value of $887,235.90.
• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.30, for a total value of $690,952.50.

Vir Biotechnology Stock Down 7.2%

NASDAQ:VIR opened at $5.63 on Wednesday. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $14.45. The firm has a market capitalization of $783.25 million, a price-to-earnings ratio of -1.56 and a beta of 1.34. The stock’s 50 day moving average price is $5.78 and its two-hundred day moving average price is $5.33.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.47). The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.98 million. Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. Vir Biotechnology’s quarterly revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.56) earnings per share. As a group, analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VIR. Connective Capital Management LLC bought a new stake in shares of Vir Biotechnology during the third quarter worth approximately $431,000. Sender Co & Partners Inc. acquired a new stake in Vir Biotechnology during the 3rd quarter worth approximately $247,000. Dark Forest Capital Management LP bought a new stake in Vir Biotechnology in the 3rd quarter valued at $817,000. XTX Topco Ltd bought a new stake in Vir Biotechnology in the 3rd quarter valued at $799,000. Finally, Prelude Capital Management LLC acquired a new position in Vir Biotechnology in the 3rd quarter valued at $108,000. 65.32% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

VIR has been the topic of several recent analyst reports. Evercore ISI initiated coverage on shares of Vir Biotechnology in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 price objective on the stock. Bank of America raised Vir Biotechnology from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $12.00 to $14.00 in a research report on Wednesday, August 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vir Biotechnology in a research report on Monday. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a research note on Monday, September 15th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).